In a recent study, published in the Sept. 29 issue of Journal of American Chemical Society, Iron-platinum alloy (FePt) nanoparticles can perform as dual modal CT/MRI molecular imaging contrast agent in clinical procedures. Chia-chun Chen, PhD, a professor in the department of chemistry at National Taiwan Normal University and his team has developed and used the water-solvable FePt nanoparticles of 3nm, 6 nm and 12 nm in diameter as dual modality contrast agent for CT/MRI molecular imaging.
According to Chen and researchers, these nanoparticles showed perfect biocompatibility and hemocompatibility in all trials which focused on imaging contrast. The biodistribution researches noted that the greatest serum concentration and circulation half-life for 12 nm-FePt, followed by 6 nm-FePt and then 3 nm-FePt . The research team created molecular expression which relies on CT/MRI dual imaging contrast impact on tumor-bearing mice and the in MBT2 cell line. The 12 nm-FePt exceeded 3 nm-FePt in both imaging systems. Chen and researchers mentioned that "These results indicate the potential of FePt nanoparticles to serve as novel multimodal molecular imaging contrast agents in clinical settings,"
